I am a
Home I AM A Search Login

Papers of the Week

Papers: 12 Sep 2020 - 18 Sep 2020

Human Studies, Pharmacology/Drug Development


2020 Sep 15

Qual Life Res

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).


To evaluate secondary outcomes including changes in functioning and disability associated with galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, in patients with chronic migraine.